MDA-MB-231 Cell Line human

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 92020424, human breast, Epithelial

• Sinónimos: MD Anderson-Metastatic Breast-231 Cells, MDA-MB231 Cells, MDA231-BRE Cells, MDAMB231 Cells
• Código UNSPSC: 41106514
• eCl@ss: 32190102

Propiedades

• origen biológico: human breast
• envase: tube of 5 μg 92020424-DNA-5UG; pkg of vial of cells 92020424-1VL
• modo de crecimiento: Adherent
• cariotipo: Modal no.′s 62 and 64, near triploid
• morfología: Epithelial
• productos: Not specified
• receptores: Not specified
• técnicas: cell culture | mammalian: suitable
• enfermedades relevantes: cancer
• Condiciones de envío: dry ice
• temp. de almacenamiento: −196°C

Descripción

Origen línea celular

Human Caucasian breast adenocarcinoma

Descripción línea celular

Isolated from pleural effusions of a breast cancer patient.

Aplicación

MDA-MB-231 has been used to study:

• the changes in the morphological pattern and gene expression of cells when grown in the presence of sera positive for anti-carbonic anhydrase I (CA I) autoantibodies
• the effects of normothermic conditioned microwave irradiation on cultured cells using an irradiation system
• the transendothelial migration rates of the cells under different shear stress levels

Perfil del ADN

STR-PCR Data: Amelogenin: X
CSF1PO: 12,13
D13S317: 13
D16S539: 12
D5S818: 12
D7S820: 8,9
THO1: 7,9.3
TPOX: 8,9
vWA: 15,18

Medio de cultivo

L15+ 2mM Glutamine + 15% Foetal Bovine SerumFBS / FCS.

Rutina de subcultivo

Split sub-confluent cultures (70-80%) 1:3 to 1:6, i.e. seeding at 3-6x10,000 cells/cm² using 0.05% Trypsin or Trypsin/EDTA; 37°C. CO₂ is not required.

Otras notas

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Cláusula de descargo de responsabilidad

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.